Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Improving Hospice Referral: Application of Regret-Based Decision Modeling at End-of-Life Care

Benjamin Djulbegovic, MD PhD, Athanasios Tsalatsanis, PhD, Rahul Mhaskar, MPH, PhD, Iztok Hozo, PhD, Branko Miladinovic, PhD, Howard Tuch, MD PhD

Blood (2016) 128 (22): 535.

https://doi.org/10.1182/blood.V128.22.535.535

Published: 2016

Journal Articles

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

Martine Extermann, MD PhD, Marina Sehovic, MD MPH, Tea Reljic, MPH, Jongphil Kim, PhD, Jeffrey E. Lancet, MD, Benjamin Djulbegovic, MD PhD

Blood (2016) 128 (22): 3998.

https://doi.org/10.1182/blood.V128.22.3998.3998

Published: 2016

Journal Articles

When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?

Jongphil Kim, Martine Extermann, MD PhD, Jeffrey E. Lancet, MD, Najla H Al Ali, Tea Reljic, MPH, Marina Sehovic, MD MPH, Varun C Dhulipala, MD, Benjamin Djulbegovic, MD PhD

Blood (2016) 128 (22): 4007.

https://doi.org/10.1182/blood.V128.22.4007.4007

Published: 2016

Journal Articles

Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients

Varun C Dhulipala, MD, Martine Extermann, MD PhD, Najla Al Ali, Jongphil Kim, Marina Sehovic, MD MPH, Tea Reljic, Benjamin Djulbegovic, MD PhD, Jeffrey E Lancet, MD

Blood (2015) 126 (23): 2505.

https://doi.org/10.1182/blood.V126.23.2505.2505

Published: 2015

Journal Articles

Meta-Analysis Evaluating Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation As Front-Line Consolidation in Chronic Lymphocytic Leukemia: Results Do Not Justify This Treatment Approach

Tea Reljic, M.S., Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD, Mohamed A Kharfan-Dabaja, MD

Blood (2014) 124 (21): 1306.

https://doi.org/10.1182/blood.V124.21.1306.1306

Published: 2014

Journal Articles

Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis

Tea Reljic, BS, Ambuj Kumar, MD, MPH, Helen Mahoney, MPH, Branko Miladinovic, PhD, Mohamed A Kharfan-Dabaja, MD, Rahul Mhaskar, MPH, PhD, Benjamin Djulbegovic, MD, PhD

Blood (2013) 122 (21): 1945.

https://doi.org/10.1182/blood.V122.21.1945.1945

Published: 2013

Journal Articles

A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia

Apuri Susmitha, MD, Taiga Nishihori, MD, Karen Lin, MD, Rachid Baz, MD, Binglin Yue, MS, Jongphil Kim, PhD, Kenneth H. Shain, MD, PhD, Elias Doumit, MD, Jose L Ochoa-Bayona, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, Benjamin Djulbegovic, MD, PhD

Blood (2013) 122 (21): 3155.

https://doi.org/10.1182/blood.V122.21.3155.3155

Published: 2013

Journal Articles

Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis

Jasmin Lacevic, Tea Reljic, BS, Najla El Jurdi, MD, Mohamed A Kharfan-Dabaja, MD, Taiga Nishihori, MD, Rami S. Komrokji, MD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2013) 122 (21): 5372.

https://doi.org/10.1182/blood.V122.21.5372.5372

Published: 2013

Journal Articles

Comparative Efficacy of Tandem Autologous Versus Autologous Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis

Mohamed A. Kharfan-Dabaja, MD, Mehdi Hamadani, M.D, Tea Reljic, William I. Bensinger, MD, Benjamin Djulbegovic, MD, PhD, Ambuj Kumar, MD, MPH

Blood (2012) 120 (21): 4519.

https://doi.org/10.1182/blood.V120.21.4519.4519

Published: 2012

Journal Articles

Maintenance Therapies for Multiple Myeloma (MM): A Direct Meta-Analysis

Helen Mahony, MPH, Ambuj Kumar, MD, MPH, Rahul Mhaskar, MPH, PhD, Branko Miladinovic, PhD, Keith Wheatley, Benjamin Djulbegovic, MD, PhD

Blood (2012) 120 (21): 4271.

https://doi.org/10.1182/blood.V120.21.4271.4271

Published: 2012

Journal Articles

Social Network Analysis (SNA) of Salvage Therapies in Multiple Myeloma (MM)

Helen Mahony, MPH, Athanasios Tsalatsanis, PhD, Rahul Mhaskar, MPH, PhD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2012) 120 (21): 4239.

https://doi.org/10.1182/blood.V120.21.4239.4239

Published: 2012

Journal Articles

Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Prosepective Randomized Controlled Studies

Mohamed A. Kharfan-Dabaja, MD, Rahul Mhaskar, MPH, PhD, Tea Reljic, Joseph Pidala, MD, MS, Janelle Perkins, PharmD, Benjamin Djulbegovic, MD, PhD, Ambuj Kumar, MD, MPH

Blood (2012) 120 (21): 4168.

https://doi.org/10.1182/blood.V120.21.4168.4168

Published: 2012

Journal Articles

Trial Sequential Analysis in Meta-Analyses of Maintenance Therapies for Multiple Myeloma.

Branko Miladinovic, PhD, Ambuj Kumar, MD, MPH, Rahul Mhaskar, MPH, PhD, Helen Mahoney, MPH, Keith Wheatley, Benjamin Djulbegovic, MD, PhD

Blood (2012) 120 (21): 2975.

https://doi.org/10.1182/blood.V120.21.2975.2975

Published: 2012

Journal Articles

Maintenance Therapies for Multiple Myeloma (MM): A Network Meta-Analysis

Helen Mahony, MPH, Ambuj Kumar, MD, MPH, Rahul Mhaskar, MPH, PhD, Branko Miladinovic, PhD, Keith Wheatley, Benjamin Djulbegovic, MD, PhD

Blood (2012) 120 (21): 236.

https://doi.org/10.1182/blood.V120.21.236.236

Published: 2012

Journal Articles

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Rachid Baz, MD, Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth Shain, MD, PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Jose Leonel Ochoa-Bayona, M.D., Daniel Sullivan, MD, Benjamin Djulbegovic, MD, PhD, William S. Dalton, PhD, MD

Blood (2011) 118 (21): 1878.

https://doi.org/10.1182/blood.V118.21.1878.1878

Published: 2011

Journal Articles

Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment Related Harms Reporting: An Analysis of National Cancer Institute's Co-Operative Group Phase III Randomized Controlled Trials

Rahul Mhaskar, MPH, PhD, Hesborn Wao, PhD, Tea Reljic, BS, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2011) 118 (21): 673.

https://doi.org/10.1182/blood.V118.21.673.673

Published: 2011

Journal Articles

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

Viet Q. Ho, PharmD, BCOP, Elizabeth Finley-Oliver, RN, Kenneth H. Shain, MD, PhD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, Rachid Baz, MD

Blood (2011) 118 (21): 5142.

https://doi.org/10.1182/blood.V118.21.5142.5142

Published: 2011

Journal Articles

Social Network Analysis (SNA) of Research Programs In Multiple Myeloma (MM)

Helen Georgiev, MPH, Athanasios Tsalatsanis, PhD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2011) 118 (21): 3144.

https://doi.org/10.1182/blood.V118.21.3144.3144

Published: 2011

Journal Articles

Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

Benjamin Djulbegovic, MD, PhD, Ambuj Kumar, MD, MPH, Branko Miladinovic, PhD, Asmita Mhaskar, MPH, Tea Reljic, BS, Sanja Galeb, BS, Rahul Mhaskar, MPH, PhD, Hozo Iztok, PhD, Dongsheng Tu, Heather Stanton, Christopher M Booth, Ralph M. Meyer, MD

Blood (2011) 118 (21): 508.

https://doi.org/10.1182/blood.V118.21.508.508

Published: 2011

Journal Articles

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, William Dalton, PhD, MD, Rachid Baz, MD

Blood (2011) 118 (21): 3979.

https://doi.org/10.1182/blood.V118.21.3979.3979

Published: 2011

NARROW

Improving Hospice Referral: Application of Regret-Based Decision Modeling at End-of-Life Care

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?

Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients

Meta-Analysis Evaluating Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation As Front-Line Consolidation in Chronic Lymphocytic Leukemia: Results Do Not Justify This Treatment Approach

Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis

A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia

Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis

Comparative Efficacy of Tandem Autologous Versus Autologous Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis

Maintenance Therapies for Multiple Myeloma (MM): A Direct Meta-Analysis

Social Network Analysis (SNA) of Salvage Therapies in Multiple Myeloma (MM)

Mycophenolate Mofetil versus Methotrexate for Prevention of Acute Graft-Versus-Host Disease: Results of a Systematic Review Limited to Prosepective Randomized Controlled Studies

Trial Sequential Analysis in Meta-Analyses of Maintenance Therapies for Multiple Myeloma.

Maintenance Therapies for Multiple Myeloma (MM): A Network Meta-Analysis

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on Quality of Treatment Related Harms Reporting: An Analysis of National Cancer Institute's Co-Operative Group Phase III Randomized Controlled Trials

Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma

Social Network Analysis (SNA) of Research Programs In Multiple Myeloma (MM)

Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only